Wikipedia -WSS

Wikipedia

author：fashion 2025-09-27 12:58:28 - browse：117

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： My chronic pain journey would have been easier knowing 5 things % STAT

hotspot

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

'Vaccine

Medicare Advantage isn’t working — for anyone

NEJM study measures Covid brain fog, impact on IQ

Redefining sustainability for the pharmaceutical industry

Cholera vaccine supplies dangerously low, outbreaks surging

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Moonlake's readout produced a cash windfall. Risks remain

PrEP can help anyone prevent HIV. Why do so few people take it?

Moonlake's readout produced a cash windfall. Risks remain

Ohio train derailment: Experts on toxic chemical risks

DIEP, the 'gold standard' of breast reconstruction, is under threat

CDC panel: People 65 and older should get a Covid spring booster shot

Heart attack and stroke risk calculators need revising

Redefining sustainability for the pharmaceutical industry

ChatGPT in medicine: STAT answers readers' burning questions

Laying a path for careers in science

hotspot

Children’s Hospital revives plan for pedestrian bridge

Doctors have an ethical obligation to be advocates

Thousands protest mob assault of women who were paraded naked in remote Indian border state

Novartis develops a rapidly manufactured CAR

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

explore

hotspot

hotspot

focus